麻豆视频

Market Trends and Insights

Gen AI-accelerated in-silico aptamer discovery

Artificial-intelligence models now predict binding affinities with close to 90% accuracy, cutting conventional SELEX cycles from months to weeks ^{[2]Source: Administration for Strategic Preparedness and Response, 鈥淧ublic Health Emergency Medical Countermeasures Enterprise Multiyear Budget: Fiscal Years 2023-2027,鈥� aspr.hhs.gov} . UltraSELEX, disclosed in 2025, completes candidate identification in a single screening round, pushing discovery throughput to unprecedented levels. AI-driven platforms collectively raised more than USD 2 billion in venture capital during 2024, validating commercial confidence in algorithm-guided selection. Firms adopting AI-enhanced workflows report 60-80% cost reductions per candidate, a differential that is redefining competitive barriers. As discovery economics improve, smaller companies are entering the aptamer market, intensifying innovation and collaboration activity.

Rising demand for ultra-sensitive diagnostics (sub-pM LoD)

Point-of-care settings and precision-medicine workflows require assays that identify biomarkers at femtomolar levels. Aptamer-based sensors routinely achieve sub-1 pM limits of detection, outperforming enzyme-linked immunoassays by 2-3 orders of magnitude. COVID-19 underscored the value of rapid, sensitive pathogen screening, catalyzing sustained investment in next-generation diagnostic formats. Electrochemical aptasensors now detect cardiac troponin at 10 pg/mL, enabling early myocardial infarction triage in emergency departments. Integration with microfluidic chips reduces sample volumes to microliters, a critical benefit for pediatric and geriatric testing scenarios. These performance gains reinforce the aptamer market鈥檚 positioning against antibody-centric technologies.

Growth of mRNA/LNP platforms enabling RNA aptamer co-formulation

Successes in mRNA vaccination have normalized lipid nanoparticle (LNP) delivery, opening co-formulation pathways for RNA aptamers. Combined LNP-aptamer constructs demonstrate 10-fold improvements in cell-specific uptake relative to naked mRNA. Pharmaceutical pipelines targeting oncology and liver disease increasingly license aptamer ligands to sharpen tissue selectivity, as evidenced by an AstraZeneca鈥揂ptamer Group collaboration announced in 2024. As formulation toolkits mature, RNA aptamers transition from research curiosities to core components of next-generation nucleic-acid medicines.

Funding surge for novel bispecific aptamer鈥揹rug conjugates

Bispecific aptamer constructs exploit dual binding to tumor antigens and immune cells, localizing potent cytotoxins while limiting systemic exposure. University of Illinois scientists reported 40% leukemia stem-cell reduction with one such construct in 2025. Venture financing for aptamer therapeutics topped USD 500 million in 2024, with bispecific programs commanding premium valuations. Regulatory review remains intricate because agencies evaluate both aptamer targeting specificity and payload safety, yet the FDA鈥檚 IZERVAY decision shows a workable path for nucleotide-modified agents. These developments elevate the therapeutic relevance of the aptamer market and expand its strategic collaborations with oncology drug developers

Intellectual-property thickets around modified nucleotides

More than 130 patents for 2'-modified nucleotides were filed between 2020-2024, creating overlapping claims that complicate freedom-to-operate analyses. Developers often negotiate complex cross-licensing deals, an expensive hurdle for smaller entrants and a deterrent to geographic expansion. Enforcement is strongest in the United States and Europe, prompting some firms to pivot early-stage R&D into jurisdictions with lighter patent scrutiny. Strategic partnerships mitigate the issue but can dilute long-term economics. Until landmark licensing frameworks emerge, intellectual-property uncertainty will remain a drag on aptamer market growth.

Analytical-grade oligo synthesis capacity bottlenecks

Demand for high-purity oligonucleotides from aptamer, antisense, and mRNA modalities outstrips current supply by an estimated 40% heading into 2026. Solid-phase synthesis struggles with diminishing coupling efficiency beyond 50-mer sequences, limiting throughput. North American plants carry the bulk of installed capacity, making the region vulnerable to supply shocks. Industry investment in enzymatic DNA synthesis and microfluidic reactors is accelerating, yet commercial-scale output is at least two years away. Near-term tightness risks delaying clinical timelines and inflating costs across the aptamer market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Global Aptamers Market Segment Analysis

DNA aptamers accounted for 57.62% of aptamer market share in 2025, reflecting their superior nuclease stability and well-established production workflows. Diagnostics developers favor DNA scaffolds for room-temperature robustness, a key requirement for decentralized testing. The aptamer market size for DNA aptamers thereby remained the largest revenue contributor, anchored by strong demand from cardiac, infectious-disease, and environmental assays.

RNA aptamers are expected to grow at a 15.22% CAGR to 2031 on the back of mRNA-lipid nanoparticle co-formulation advances that mitigate historical stability challenges. Modified XNA forms achieve binding affinities up to 100-fold stronger than native sequences, albeit within a complex patent landscape. Pharmaceutical firms are signing option deals that attach milestone-rich structures to access RNA aptamer intellectual property, signaling confidence in clinical translation. This momentum diversifies the product mix and reinforces technology-driven competition within the aptamer market.

Diagnostics retained 45.90% share of the aptamer market size in 2025, underpinned by high-sensitivity biosensor rollouts in infectious-disease and cardiac triage settings. Laboratories embrace aptamer-based electrochemical and FET platforms because they deliver antibody-level specificity without cold-chain dependence.

Therapeutics exhibit the fastest expansion at 15.44% CAGR, a trajectory catalyzed by IZERVAY鈥檚 2023 approval and encouraging oncology proof-of-concept data. The aptamer market size for therapeutics is projected to close the gap with diagnostics as bispecific conjugates reach clinical-phase milestones. Persistent awareness gaps among clinicians constitute a soft barrier, yet growing publication volume and targeted education are narrowing this divide, positioning therapeutic programs as the next major revenue pillar.

Conventional SELEX retained 49.12% of the aptamer market share in 2025, a testament to entrenched protocols and sunk capital in legacy equipment. Academic labs value its flexibility in accommodating diverse targets, sustaining baseline demand.

Microfluidic SELEX is forecast to register a 16.05% CAGR to 2031. Magnetically activated continuous deflection chips demonstrated nanomolar-affinity aptamer isolation in six rounds, half the cycle count of traditional approaches pubs.rsc.org. Automated reagent handling slashes consumable costs ten-fold, broadening access for smaller institutes and contract research organizations. As reagent savings compound, the aptamer market expects a steady pivot toward microfluidic workflows, reshaping supplier demand for instrumentation and consumables.

Pharmaceutical and biotechnology companies commanded 40.70% share of the aptamer market size in 2025 and are expanding at 16.78% CAGR. Their participation underscores technology maturation and validates regulatory clarity for nucleotide-modified products. Capital-rich firms also finance scalability upgrades in oligonucleotide manufacturing, indirectly benefiting the entire value chain.

Contract research organizations gain traction as outsourcing partners, filling expertise gaps in SELEX optimization and regulatory documentation. Academic institutes continue to seed innovation, while hospital laboratories adopt FDA-cleared aptamer assays as reimbursement coverage stabilizes. The Standard BioTools-SomaLogic merger exemplifies a consolidation wave that combines tool providers with large bio-databases to offer integrated discovery-to-diagnostics services. Such moves reinforce competitive scale and deepen data moats inside the aptamer market.

Geography Analysis

North America Aptamers Market

North America held 44.10% aptamer market share in 2025 on the strength of its established biotech ecosystem, supportive regulatory framework, and USD 79.5 billion PHEMCE funding pipeline. FDA guidance following IZERVAY鈥檚 approval clarified chemistry-manufacturing-controls expectations for oligonucleotide impurities, accelerating therapeutic filings. Venture-capital inflows and well-capitalized instrument suppliers foster continuous platform upgrades. Production bottlenecks in analytical-grade oligos could temporarily cap growth, but ongoing investments in enzymatic synthesis plants are expected to ease pressure from 2027 onward.

Europe Aptamers Market

Europe delivers steady revenue backed by advanced healthcare infrastructure and coordinated regulatory oversight from the European Medicines Agency. Germany鈥檚 analytical-instrumentation strength and France鈥檚 biotech research clusters provide fertile ground for diagnostic innovation. The United Kingdom maintains momentum despite Brexit through partnerships such as Aptamer Group鈥檚 projects in liver fibrosis and Alzheimer鈥檚 testing. Reimbursement policies favor high-value assays, making Europe an attractive launchpad for premium diagnostics and early-phase therapeutics.

APAC Aptamers Market

Asia-Pacific is the fastest-growing region with a projected 17.28% CAGR through 2031. China invested more than CNY 20 billion (USD 2.8 billion) of public funds into biotech in 2023 and now hosts 27% of the global pipeline merics.org. Japan鈥檚 sophisticated pharma sector and Australia鈥檚 translational-research hubs further expand the addressable base. India and South Korea provide cost-competitive manufacturing and electronics capabilities that align with microfluidic SELEX automation. Intellectual-property complexities persist, yet government incentives and expanding local manufacturing temper risk perceptions, positioning the region as an essential growth engine for the aptamer market

Regulatory Landscape

Aptamer therapeutics are increasingly regulated within broader oligonucleotide frameworks rather than as stand-alone biologics, which tightens expectations on nonclinical packages and CMC controls. In November 2024, the US FDA published a draft guidance on Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics that explicitly includes aptamers in scope, reinforcing the need for fit-for-purpose toxicology and pharmacology plans that align with oligonucleotide modality risks.

In Europe, the European Medicines Agency released a draft Guideline on the Development and Manufacture of Oligonucleotides for public consultation in July 2024, emphasizing integrated control strategies for synthetic oligonucleotides, including aptamers. The draft also highlights potency testing options at the active substance or finished drug product stage, which raises the bar for analytical methods that verify secondary structure integrity and supports more standardized review pathways across developers.

Value Chain Analysis

The aptamers value chain starts with target selection and library design, often supported by AI-enabled in-silico screening, and then moves into SELEX-based selection (conventional, cell-based, or microfluidic variants) and lead optimization using chemically modified nucleotides to tune stability and affinity. Downstream steps focus on high-purity oligonucleotide synthesis, purification, and analytical characterization, including assays that confirm structure-function, before formulation and integration into end products such as diagnostic reagents, lateral-flow formats, sequencing and PCR components, or therapeutic modalities like aptamer-drug conjugates.

Commercialization is increasingly platform-led, with developers monetizing through fee-for-service discovery, repeat development programs with large pharma, and licensing into adjacent reagent and genomics workflows. Recent examples include Aptamer Group signing a licensing agreement with Twist Bioscience in December 2025 for Optimer binders used in hot-start PCR and next-generation sequencing products, and Aptamer Group expanding multi-target Optimer development work with a top-five pharmaceutical partner in 2025. On the therapeutic side, collaborations extend the chain into radiopharmaceutical and conjugate development, including Aptamer Group launching a targeted radiopharmaceutical program with Radiopharmium Ltd in March 2026 and Ribomic entering a joint research agreement with SK Plasma in January 2026 to develop aptamer-drug conjugates using its RiboART system.

Market Opportunities and Future Outlook

Discovery automation and scalable binder generation are a practical whitespace for aptamers, since throughput and reproducibility shape how quickly aptamers can be inserted into diagnostics, reagent kits, and therapeutic discovery funnels. In April 2026, Aptamer Group raised GBP 4.1 million and deployed capital expenditure into new automation equipment to increase parallel discovery across small molecules, proteins, and cell-based targets, illustrating how workflow and capacity investments can translate into more programs that can be commercialized via services and licensing.

Therapeutics add further opportunity where aptamers act as targeting ligands or active agents in combination regimens, supported by visible clinical and translational activity. In April 2026, Nature Communications published results from the GLORIA trial expansion reporting median progression-free survival of 9.1 months in newly diagnosed glioblastoma patients treated with NOX-A12 combined with radiotherapy and bevacizumab, reinforcing clinical interest in aptamer-based approaches. In stroke, the European Stroke Journal reported the ongoing Phase 2 RAISE trial for the RNA aptamer BB-031, with Part B enrolling up to 180 patients, supporting continued pipeline progression that can expand demand for GMP-grade oligonucleotide manufacturing, analytical testing, and specialized formulation capabilities.